Analgesic effect of N-palmitoylglycine and N-palmitoyl-5-aminolevulinic acid alone and in combination with diclofenac sodium
COUNTRY OF ORIGIN
BelarusIDENTIFIER
TO4858PUBLISHED
2022-03-11LAST UPDATE
2022-03-13DEADLINE
Linked profile in other language
Responsible
Tatiana Khrustaleva
+375 17 378 1630
biblio@fizio.bas-net.by
+375 17 378 1630
biblio@fizio.bas-net.by
Summary
The Institute of Physiology offers research results and technology for the analgesic effect of N-palmitoylglycine and N-palmitoyl-5-aminolevulinic acid alone and in combination with diclofenac sodium to consumers under a commercial agreement with technical assistance and is looking for partners to conclude an agreement on scientific cooperation.
Description
Neuropathic pain affects approximately 8% of the world's population. Chronic unbearable pain significantly impairs the lives of such patients up to the development of psychiatric symptoms such as depression. Drugs that effectively relieve pain are characterized by serious side effects in some patients. In this regard, it is relevant to search for ways to effectively alleviate pain, which at the same time will be characterized by the absence of side effects.
The analgesic effect of derivatives of fatty acid amides N-palmitoylglycine and N-palmitoyl-5-aminolevulinic acid was revealed in experimental peripheral neuropathy. It has been established that the use of the mentioned substances in combination with diclofenac sodium is accompanied by a synergistic analgesic effect. Studies of the general toxicity of palmitoylglycine and palmitoyl-5-aminolevulinic acid (in the form of inclusion complexes in liposomes) made it possible to classify them as low-toxic substances. When studying the toxicity of these lipids with their repeated administration, it was found that they are characterized by a weakly expressed functional cumulation, and in general their toxic effect is much weaker than that of diclofenac sodium.
The analgesic effect of derivatives of fatty acid amides N-palmitoylglycine and N-palmitoyl-5-aminolevulinic acid was revealed in experimental peripheral neuropathy. It has been established that the use of the mentioned substances in combination with diclofenac sodium is accompanied by a synergistic analgesic effect. Studies of the general toxicity of palmitoylglycine and palmitoyl-5-aminolevulinic acid (in the form of inclusion complexes in liposomes) made it possible to classify them as low-toxic substances. When studying the toxicity of these lipids with their repeated administration, it was found that they are characterized by a weakly expressed functional cumulation, and in general their toxic effect is much weaker than that of diclofenac sodium.
Advantages and Innovations
The research results provide a basis for the development of drugs or biologically active food supplements, which by themselves will alleviate the pain associated with arthritis and neuropathy, and in combination with non-steroidal anti-inflammatory drugs will increase the effect of the latter, while reducing the likelihood of their side effects. .
Stage of development
Under development/lab tested (TRL4)
Funding source
State budged
Internal
Internal
IPR status
Exclusive rights
Secret know-how
Secret know-how
Sector group
BioChemTech
Healthcare
Healthcare
Client information
Type
R&D institution
Year established
1953
NACE keywords
Q.86.90 - Other human health activities
M.72.11 - Research and experimental development on biotechnology
M.72.19 - Other research and experimental development on natural sciences and engineering
M.74.90 - Other professional, scientific and technical activities n.e.c.
M.72.11 - Research and experimental development on biotechnology
M.72.19 - Other research and experimental development on natural sciences and engineering
M.74.90 - Other professional, scientific and technical activities n.e.c.
Turnover (in EUR)
1-10M
Already engaged in transnational cooperation
Yes
Additional comments
The Institute is a leading scientific institution coordinating physiological research in the Republic of Belarus. The institute successfully carries out fundamental and applied research aimed at developing methods for the prevention and correction of pathological conditions of hypoxic, ischemic and inflammatory origin, and develops new devices and methods for their therapeutic and prophylactic use. The main scientific activity of the divisions is currently focused on studying the mechanisms of the formation of pathological conditions of the body (primarily hypoxic and neurodestructive) and substantiating new technologies for prevention, treatment and rehabilitation. Particular attention is paid to the development of complex methods for the treatment of malignant tumors using effectors of the blockade of metabolism and high-intensity pulsed magnetic fields and methods for controlling the proliferation of tumor cells based on changes in the functional state of neuroreceptors in vitro and in vivo, as well as the development of a method for immunotherapy of patients suffering from pancreatic cancer. , using autologous dendritic cells primed with tumor antigens and elucidating new mechanisms of tumor formation, substantiation of prevention methods. Research is underway on the molecular mechanisms of proliferation, differentiation, and oncogenesis; physiological and therapeutic effect of physical factors and the development of new technologies of physiotherapy and physiotherapy equipment and experimental analysis of the positive and negative aspects of the use of nanoparticles and heterocyclic compounds in biomedical technologies. The neurophysiological bases of dysregulation of the functions of internal organs during ischemia of the nervous tissue of various origins are being studied. Works on the physiology of nutrition and sports are being carried out. Preclinical studies of drugs and nanomaterials are underway.
Languages spoken
English
Russian
Russian
Information about partnership
Type of partnership considered
Commercial agreement with technical assistance
Research cooperation agreement
Research cooperation agreement
Type and role of partner sought
Consumers interested in purchasing of N-Palmitoylglycine and N-Palmitoyl-5-Aminolevulic Acid research results and technologies for pain relief alone and in combination with Diclofenac Sodium based on a commercial agreement with technical support.
Partners interested in concluding an research cooperation agreement.
Partners interested in concluding an research cooperation agreement.
Type and size of partner sought
251-500
SME 51-250
SME 11-50
SME <= 10
R&D Institution
University
SME 51-250
SME 11-50
SME <= 10
R&D Institution
University
Views: 1582
Statistics since 11.03.2022 15:10:04
Statistics since 11.03.2022 15:10:04